Hong Kong Finance Chief Questions Moody’s Over Debt Downgrade

Moody’s Investors Service’s decision to downgrade Hong Kong’s debt rating last week was based on “shallow” evidence, Hong Kong Financial Secretary Paul Chan wrote in a blog on Sunday. “The evidence on which the ratings company mechanically ... ( read original story ...)

HK Financial Secretary questions Moody’s over debt downgrade

... s debt rating based on the very close economic relationship between Hong Kong and the mainland is shallow,” Chan wrote in a blog on the official website of the financial secretary. Enhancing cooperation with the mainland cannot be considered ... ( read original story ...)

BOC Aviation buys six Airbus aircraft for $1.05 billion

HONG KONG BOC Aviation Ltd on Friday said it would buy six new aircraft from Airbus for an aggregate list price of $1.05 billion as the aircraft lessor builds its balance sheet by investing in modern, efficient and in-demand aircraft. The Hong Kong-listed ... ( read original story ...)

BOC Aviation buys six Airbus aircraft for $1.05 bln

HONG KONG, May 26 (Reuters) - BOC Aviation Ltd on Friday said it would buy six new aircraft from Airbus for an aggregate list price of $1.05 billion as the aircraft lessor builds its balance sheet by investing in modern, efficient and in ... ( read original story ...)

Samsung battles Apple in SAR

namely DBS Hong Kong, BOC Hong Kong, Citibank and Dah Sing Bank.Samsung Pay directly challenges Apple Pay, launched last year in partnership with some of the SAR's largest banks - HSBC, ... The global battle between Apple and Samsung shifts to Hong Kong ... ( read original story ...)

Late-comer Samsung Pay goes live in Hong Kong

BOC Credit Card, a unit of Bank of China Hong Kong, said customers who pay with Samsung Pay using its Visas or Mastercards will be eligible for discounts at retailers Mannings and 7-Eleven. Citi is offering customers free Samsung Galaxy S8s and a cash ... ( read original story ...)

WuXi Biologics to launch $513 mln Hong Kong IPO on Thursday -IFR

HONG KONG May 24 WuXi Biologics (Cayman) Inc, a Chinese contract drug research and development company, plans to launch on Thursday an initial public offering of up to $513 million in Hong Kong, IFR reported, citing people close to the deal. The company is ... ( read original story ...)